Medicine – Multiple Sclerosis

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). It affects the brain, spinal cord, and optic nerves and is characterised by episodes of neurological dysfunction caused by inflammation, demyelination, and eventually varying degrees of axonal loss.

A central diagnostic concept is that lesions are disseminated in space and time—that is, they occur in different parts of the CNS and at different points in time.

1. Pathophysiology

MS is primarily an immune-mediated disease directed against components of CNS myelin and related neural tissue.

Both T-cell and B-cell immune mechanisms are involved.

Inflammatory cells cross the blood–brain barrier and contribute to:

Demyelination.

Oligodendrocyte injury.

Axonal damage.

Formation of plaques within CNS white matter and other regions.

Over time, repeated inflammatory injury can lead to irreversible neurodegeneration and disability.

2. Dissemination in Space and Time

The phrase “disseminated in time and place” is better expressed as:

Dissemination in space + dissemination in time.

Dissemination in space means lesions are found in different characteristic CNS locations.

Dissemination in time means there is evidence that lesions developed at different times.

This principle is central to modern MS diagnosis.

3. Typical Sites of Lesions

MS lesions commonly occur in areas such as:

Periventricular white matter.

Juxtacortical or cortical regions.

Infratentorial structures.

Spinal cord.

Optic nerves.

These locations help distinguish MS from many other white-matter disorders.

4. Clinical Presentation

MS can present in many different ways because lesions can occur throughout the CNS.

The percentages in older notes vary widely between studies, so they are best treated as historical approximations rather than fixed frequencies.

Common presenting symptoms include:

Weakness.

Optic neuritis.

Paraesthesiae or sensory disturbance.

Diplopia.

Bladder dysfunction.

Vertigo or imbalance.

5. Weakness

Patients may develop weakness affecting one or more limbs.

Because MS involves the CNS, weakness often has upper motor neurone features, such as:

Spasticity.

Hyperreflexia.

Extensor plantar responses.

Weakness may be focal, asymmetric, or involve both legs depending on lesion location.

6. Optic Neuritis

Optic neuritis is a classic presentation of MS.

Patients typically develop:

Subacute unilateral visual loss.

Pain on eye movement.

Reduced colour saturation, especially red.

Central scotoma.

Relative afferent pupillary defect.

The optic disc may appear normal initially if the inflammation is retrobulbar.

7. Sensory Symptoms

Paraesthesiae are common.

Patients may describe:

Pins and needles.

Numbness.

Burning sensations.

Tingling.

Electric-shock sensations.

A particularly characteristic symptom is Lhermitte phenomenon, in which flexion of the neck produces an electric-shock-like sensation down the spine or limbs due to cervical cord involvement.

8. Diplopia

Diplopia may occur because MS commonly affects brainstem pathways controlling eye movements.

One classic finding is internuclear ophthalmoplegia (INO) caused by involvement of the medial longitudinal fasciculus.

This produces impaired adduction of one eye with nystagmus of the abducting eye.

Bilateral INO in a young adult is strongly suggestive of MS.

9. Bladder Dysfunction

Bladder symptoms may occur due to spinal cord or supraspinal involvement.

Patients may develop:

Urgency.

Frequency.

Urge incontinence.

Difficulty emptying the bladder.

Retention in more advanced disease.

The original 5% figure should not be treated as universal because bladder dysfunction becomes common during the course of established MS.

10. Vertigo and Balance Problems

Brainstem and cerebellar lesions can cause:

Vertigo.

Ataxia.

Tremor.

Dysarthria.

Nystagmus.

Balance disturbance may significantly impair mobility even when limb strength is relatively preserved.

11. Other Important Symptoms

MS may also cause:

Fatigue.

Cognitive dysfunction.

Spasticity.

Neuropathic pain.

Sexual dysfunction.

Bowel dysfunction.

Mood disturbance.

Heat sensitivity.

Symptoms can fluctuate and may worsen temporarily with fever or increased body temperature.

12. Uhthoff Phenomenon

Uhthoff phenomenon refers to temporary worsening of previous neurological symptoms when body temperature rises.

This may occur with:

Exercise.

Hot weather.

Fever.

Hot baths.

It reflects impaired conduction through previously demyelinated nerve fibres rather than formation of a new lesion.

13. Relapsing-Remitting MS

The most common initial disease pattern is relapsing-remitting MS (RRMS).

Patients experience episodes of new or worsening neurological symptoms called relapses, followed by partial or complete recovery.

Relapses usually develop over hours to days and persist for at least 24 hours in the absence of fever or infection.

14. Secondary Progressive MS

Some patients with relapsing-remitting disease later develop secondary progressive MS (SPMS).

This is characterised by gradual worsening of neurological disability independent of clearly defined relapses.

Modern disease-modifying treatment aims partly to reduce the chance or delay the development of progressive disability.

15. Primary Progressive MS

A further important category is primary progressive MS (PPMS).

In this form, disability gradually worsens from the beginning without a typical initial relapsing-remitting pattern.

Patients often present with progressive spinal cord symptoms, particularly worsening gait and lower-limb stiffness.

16. MRI

MRI is the most important imaging investigation in suspected MS.

Typical lesions appear as areas of high signal intensity on T2-weighted and FLAIR sequences.

Characteristic distributions include:

Periventricular lesions.

Juxtacortical/cortical lesions.

Infratentorial lesions.

Spinal cord lesions.

17. Gadolinium Enhancement

Active inflammatory lesions may enhance after administration of gadolinium contrast.

The simultaneous presence of enhancing and non-enhancing lesions can provide evidence of lesions of different ages and therefore support dissemination in time.

Serial MRI can also demonstrate new lesions developing over time.

18. Dawson Fingers

A classic MRI feature is Dawson fingers.

These are ovoid periventricular lesions oriented roughly perpendicular to the lateral ventricles along medullary veins.

They are strongly associated with MS but are not completely specific.

19. Visual Evoked Potentials

Visual evoked potentials (VEPs) measure electrical responses in the visual pathway after a visual stimulus.

Demyelination slows nerve conduction and can produce delayed P100 latency.

This can provide evidence of previous optic pathway demyelination even when the patient has recovered clinically.

VEPs are less central to diagnosis than MRI but can still be useful in selected cases.

20. CSF Oligoclonal Bands

CSF examination may reveal oligoclonal IgG bands that are present in the CSF but absent from serum.

This indicates intrathecal immunoglobulin production.

Oligoclonal bands are found in many patients with MS and can support the diagnosis.

However, they are not specific to MS and may occur in other inflammatory or infectious CNS disorders.

21. CSF IgG Index

The IgG index may also be raised.

Routine CSF findings are otherwise often relatively mild:

Glucose usually normal.

Protein normal or mildly raised.

White cells normal or mildly lymphocytic.

Marked pleocytosis or very high protein should prompt consideration of another diagnosis.

22. Modern Diagnosis

Modern diagnosis generally uses the McDonald criteria, which combine:

Clinical attacks.

MRI evidence.

Dissemination in space.

Dissemination in time.

CSF oligoclonal bands in appropriate circumstances.

The diagnosis also requires exclusion of better alternative explanations.

23. Management Principles

MS management is ideally multidisciplinary.

Care may involve:

Neurology.

Physiotherapy.

Occupational therapy.

Specialist nursing.

Ophthalmology.

Urology.

Rehabilitation services.

Psychological and social support.

Management includes acute relapse treatment, disease-modifying therapy, symptom control, and rehabilitation.

24. Acute Relapse Treatment

Significant acute relapses are commonly treated with high-dose corticosteroids.

A traditional regimen is intravenous methylprednisolone for 3–5 days, although high-dose oral regimens may also be used in appropriate settings.

Steroids accelerate recovery from the relapse but do not necessarily improve the ultimate long-term neurological outcome from that particular attack.

25. Disease-Modifying Therapy

Modern MS treatment includes a wide range of disease-modifying therapies (DMTs) designed to reduce relapse frequency, MRI activity, and disability accumulation.

These include injectable, oral, and monoclonal-antibody treatments.

Choice depends on disease activity, patient factors, pregnancy considerations, adverse-effect profile, monitoring requirements, and local guidelines.

26. Interferon-β

Interferon-beta was one of the earliest widely used disease-modifying therapies.

It can reduce:

Relapse frequency.

MRI inflammatory activity.

Disease activity in relapsing forms of MS.

However, it is no longer the only or necessarily preferred treatment because many newer DMTs are available.

27. Interferon-β and Secondary Progressive MS

The older statement that interferon-beta is routinely used in secondary progressive MS needs qualification.

Its benefit is mainly in relapsing disease with ongoing inflammatory activity.

In secondary progressive MS without active relapses or MRI inflammatory activity, interferon-beta is generally much less useful.

Modern treatment for active progressive disease may involve other disease-modifying agents depending on the exact phenotype and local approval.

28. Symptomatic Treatment

Symptom management is an important part of long-term care.

Examples include treatment for:

Spasticity.

Neuropathic pain.

Bladder dysfunction.

Fatigue.

Depression.

Mobility impairment.

Sexual dysfunction.

Physiotherapy and rehabilitation are often as important as medication for maintaining function and independence.

29. Multiple Sclerosis – Note Form

Definition: chronic immune-mediated inflammatory demyelinating disease of the CNS.

Pathology: inflammation + demyelination + axonal loss.

Diagnostic principle: lesions disseminated in space and time.

Common sites: periventricular, juxtacortical/cortical, infratentorial, spinal cord and optic nerve.

Weakness: often upper motor neurone type with spasticity and hyperreflexia.

Optic neuritis: painful subacute unilateral visual loss with red desaturation.

Sensory symptoms: paraesthesiae, numbness and Lhermitte phenomenon.

Diplopia: may result from internuclear ophthalmoplegia.

Bladder dysfunction: urgency, frequency, retention or incontinence may occur.

Vertigo/ataxia: due to brainstem or cerebellar lesions.

MRI: T2/FLAIR hyperintense white-matter lesions in characteristic locations.

Active lesions: may enhance with gadolinium.

VEP: delayed visual evoked response due to slowed conduction.

CSF: oligoclonal IgG bands present in CSF but not serum; not completely specific.

Acute relapse: high-dose corticosteroids such as methylprednisolone.

Long-term treatment: disease-modifying therapy selected according to disease type and activity.

Interferon-β: reduces relapses in relapsing forms of MS but is only one of many modern DMT options.

Key Clinical Pattern

Remember MS as:

Young adult + neurological episodes separated in time + lesions in different CNS locations.

The most useful clues are:

Optic neuritis.

Sensory disturbance.

Upper motor neurone weakness.

Internuclear ophthalmoplegia.

Ataxia.

Bladder dysfunction.

And the key investigations are:

MRI → characteristic T2/FLAIR lesions.

CSF → oligoclonal bands.

VEP → delayed conduction.

The core diagnostic concept is:

Multiple sclerosis = dissemination in space + dissemination in time.